1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

HHS Rebate Rule: At Least We Know Who Is In Charge

 
• By Michael McCaughan

HHS proposal to eliminate the “safe harbor” that allows for prescription drug rebates took a long time to clear White House review. Its release sends a clear message that US HHS Secretary Azar wants to lead the drug pricing debate in 2019.

Azar_Alex_1902_400px.jpg
HHS Secretary Azar

It may be hard to predict what the elimination of the “safe harbor” that has allowed for prescription drug rebates in the US will mean for participants in the pharmaceutical supply chain, but the release of the rule makes one thing very clear: HHS Secretary Alex Azar intends to lead the drug pricing debate in 2019.

The rule, which would eliminate the protection on prescription drug rebates from prosecution under federal anti-kickback, will clearly have far-reaching...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

Real Savings: Medicare-Negotiated Discounts On Cancer Drugs Range From 40%-60%

 
• By Cathy Kelly

Because they are not heavily rebated already, the discounts on four cancer treatments and a trio of other specialty drugs may benefit patients and the government more than others in the IPAY 2027 class.

Trump’s Semaglutide Most Favored Nation Price Will ‘Supersede’ Medicare MFP

 
• By Cathy Kelly

The Medicare negotiated price is slightly higher than the Most Favored Nation price recently announced by the Trump Administration.

Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge

 
• By Manas Mishra

The second cycle of IRA price negotiations could result in price cuts as high as 85% to the 2024 list prices, but the mean discount across the 15 negotiated drugs appears similar to the previous round.

Biologics To Dominate 2028 Medicare Negotiation Cycle As Eligibility Expands To Part B

 
• By Cathy Kelly

The inclusion of Medicare Part B drugs in the program for the first time will sweep in several biologics, even though heavy hitters Keytruda and Opdivo will not be among them.

More from Government Payers

Biologics To Dominate 2028 Medicare Negotiation Cycle As Eligibility Expands To Part B

 
• By Cathy Kelly

The inclusion of Medicare Part B drugs in the program for the first time will sweep in several biologics, even though heavy hitters Keytruda and Opdivo will not be among them.

Medicare Part D Plan ‘Instability’ May Prompt Demands For More Drug Price Concessions

 
• By Cathy Kelly

Is the $2,000 out-of-pocket spending limit in Part D too ‘aggressive’? Manufacturers could be targeted when policymakers seek a solution for the disarray in the standalone plan market caused in part by the cap.

Trump Most Favored Nation Pricing Is More ‘GENEROUS’ In 2025 Than 2020

 
• By Michael McCaughan

The Trump Administration’s formula for ‘Most Favored Nation’ pharmaceutical pricing has evolved since the first Trump team proposed MFN pricing for Medicare in 2020. The ‘GENEROUS’ Medicaid model in 2025 is indeed more generous to manufacturers – though still not an attractive proposition.